Work

Abstract 4365761: Acoramidis Lowers NT-proBNP in a Larger Proportion of ATTRibute-CM Study Participants With Transthyretin Amyloid Cardiomyopathy Compared with Placebo, Independent of Atrial Fibrillation Status

Year: 2025

Type: conference-abstract

Source: Circulation

DOI: 10.1161/circ.152.suppl_3.4365761

Authors: Mathew Maurer, Kevin Alexander, Laura Obici, Steen Poulsen, James Januzzi, Ronald Witteles, Wael Jaber, Yevgeniy Brailovsky, Kai Vogtlaender, Adam Castano, Jean-Francois Tamby, Jonathan Fox, Sumeet Mitter, Mazen Hanna, Brett Sperry

Institutions: Columbia University Irving Medical Center, Stanford University, Policlinico San Matteo Fondazione, Aarhus University Hospital, Baim Institute for Clinical Research, Stanford Medicine, Cleveland Clinic, Bayer (Germany), Inova Health System, Saint Luke's Hospital

Language: English

Topic: Amyloidosis: Diagnosis, Treatment, Outcomes

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4415791218

Cites:

Cited by:

Related to: